These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 25736528)

  • 1. Orodispersible drug formulations for children and elderly.
    Slavkova M; Breitkreutz J
    Eur J Pharm Sci; 2015 Jul; 75():2-9. PubMed ID: 25736528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
    Thabet Y; Slavkova M; Breitkreutz J
    Expert Opin Drug Deliv; 2018 Mar; 15(3):261-270. PubMed ID: 29284286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in orodispersible films for drug delivery.
    Hoffmann EM; Breitenbach A; Breitkreutz J
    Expert Opin Drug Deliv; 2011 Mar; 8(3):299-316. PubMed ID: 21284577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Printing medicines as orodispersible dosage forms: Effect of substrate on the printed micro-structure.
    Planchette C; Pichler H; Wimmer-Teubenbacher M; Gruber M; Gruber-Woelfler H; Mohr S; Tetyczka C; Hsiao WK; Paudel A; Roblegg E; Khinast J
    Int J Pharm; 2016 Jul; 509(1-2):518-527. PubMed ID: 26541301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics.
    Thabet Y; Klingmann V; Breitkreutz J
    J Clin Pharmacol; 2018 Oct; 58 Suppl 10():S26-S35. PubMed ID: 30248193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study.
    Ranmal SR; Cram A; Tuleu C
    Int J Pharm; 2016 Nov; 514(1):296-307. PubMed ID: 27863675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally disintegrating drug carriers for paediatric pharmacotherapy.
    Kean EA; Adeleke OA
    Eur J Pharm Sci; 2023 Mar; 182():106377. PubMed ID: 36634740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements.
    Cilurzo F; Musazzi UM; Franzé S; Selmin F; Minghetti P
    Drug Discov Today; 2018 Feb; 23(2):251-259. PubMed ID: 29030242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery and formulations.
    Breitkreutz J; Boos J
    Handb Exp Pharmacol; 2011; 205():91-107. PubMed ID: 21882107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
    Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
    Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patent landscape of pediatric-friendly oral dosage forms and administration devices.
    Karavasili C; Gkaragkounis A; Fatouros DG
    Expert Opin Ther Pat; 2021 Jul; 31(7):663-686. PubMed ID: 33605825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of acceptability of oral paediatric medicines: a review.
    Mistry P; Batchelor H;
    J Pharm Pharmacol; 2017 Apr; 69(4):361-376. PubMed ID: 27524471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient centric formulations for paediatrics and geriatrics: Similarities and differences.
    Hanning SM; Lopez FL; Wong IC; Ernest TB; Tuleu C; Orlu Gul M
    Int J Pharm; 2016 Oct; 512(2):355-359. PubMed ID: 26976504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the production methods of orodispersible films.
    Musazzi UM; Khalid GM; Selmin F; Minghetti P; Cilurzo F
    Int J Pharm; 2020 Feb; 576():118963. PubMed ID: 31857185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physicochemical characterisation of fluids and soft foods frequently mixed with oral drug formulations prior to administration to children.
    Kersten E; Barry A; Klein S
    Pharmazie; 2016 Mar; 71(3):122-7. PubMed ID: 27183705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orodispersible Films for Compounding Pharmacies.
    Ferreira AO; Brandão MAF; Raposo FJ; Polonini HC; Raposo NRB
    Int J Pharm Compd; 2017; 21(6):454-461. PubMed ID: 29220334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects.
    van Riet-Nales DA; Schobben AF; Vromans H; Egberts TC; Rademaker CM
    Arch Dis Child; 2016 Jul; 101(7):662-9. PubMed ID: 26979250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral films as perspective dosage form].
    Walicová V; Gajdziok J
    Ceska Slov Farm; 2016; 65(1):15-21. PubMed ID: 27118500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
    Giacoia GP; Taylor-Zapata P; Zajicek A
    Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outlining critical quality attributes (CQAs) as guidance for the development of orodispersible films.
    Borges AF; Silva C; Coelho JF; Simões S
    Pharm Dev Technol; 2017 Mar; 22(2):237-245. PubMed ID: 27346557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.